Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

NIH 2NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3

Conditions

Carcinoma, Non-Small-Cell Lung 126Lung Neoplasms 51Triple Negative Breast Neoplasms 35Breast Neoplasms 34Small Cell Lung Carcinoma 30Ovarian Neoplasms 27Squamous Cell Carcinoma of Head and Neck 25Neoplasm Metastasis 21Fallopian Tube Neoplasms 20Endometrial Neoplasms 19Neoplasms 17Parkinson Disease 4, Autosomal Dominant Lewy Body 14Head and Neck Neoplasms 13Colorectal Neoplasms 11Carcinoma 11Prostatic Neoplasms 9Oropharyngeal Neoplasms 9Esophageal Neoplasms 9Urinary Bladder Neoplasms 8Carcinoma, Transitional Cell 8Pancreatic Neoplasms 7Carcinoma, Squamous Cell 7Lung Diseases 6Laryngeal Neoplasms 6Carcinoma, Ovarian Epithelial 6Adenocarcinoma of Lung 6Uterine Cervical Neoplasms 5Respiratory Tract Neoplasms 5Mouth Neoplasms 5Mesothelioma 5

Interventions

Magnetic Resonance Spectroscopy 5Cyclophosphamide 5dinutuximab 3Topotecan 3Etoposide 3Doxorubicin 3Carboplatin 3Biopsy 3sargramostim 2Vincristine 2Thiotepa 2Stem Cell Transplantation 2Specimen Handling 2Radiation 2Platinum 2Melphalan 2Isotretinoin 2Colony-Stimulating Factors 2Cisplatin 21,2-diaminocyclohexaneplatinum II citrate 2iberdomide 1gallium Ga 68 dotatate 1fludarabine 1Watchful Waiting 1Transurethral Resection of Bladder 1Temozolomide 1Razoxane 1Radiotherapy 1Proton Therapy 1Observation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Ganglioneuroblastoma × Carboplatin × 90 days × Clear all
NCT06172296 2026-06-03

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

National Cancer Institute (NCI)

Phase 3 Recruiting
478 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

NCT03786783 2026-06-02

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

National Cancer Institute (NCI)

Phase 2 Completed
42 enrolled 12 charts
CNS

Ganglioneuroblastoma

NCT02176967 2026-05-05

Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma

Children's Oncology Group

Phase 3 Active not recruiting
621 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡